Biopharma
Alpha Cognition secures key US patent for traumatic brain injury treatment
The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL
- By IPP Bureau
| April 08, 2026
Alpha Cognition, the biopharmaceutical company pioneering treatments for neurodegenerative disorders, has announced a major intellectual property win for traumatic brain injury treatment.
The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL, and provides protection through 2045. The move aligns with the company’s long-term strategy to maximize the lifecycle and commercial potential of its lead assets.
“This patent marks an important milestone in expanding our platform beyond Alzheimer’s disease,” said Michael McFadden, CEO of Alpha Cognition.
“It underscores the innovation behind ALPHA-1062 while reinforcing the long-term value of ZUNVEYL. Traumatic brain injury represents a significant unmet medical need, with an estimated total addressable market of $14 billion and no approved therapies. We believe this creates a compelling first-mover opportunity.”
McFadden added, “By advancing ALPHA-1062 into TBI, we are positioning Alpha Cognition to address a large, underserved patient population while enhancing the commercial potential of our pipeline. This milestone reflects our disciplined approach to portfolio expansion and our commitment to delivering sustained shareholder value.”
